Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Seminars in Dialysis|September 19, 2014
Preserving residual renal function in dialysis: what we knowNikunjkumar Patel, Susie L Hu
Advanced Drug Delivery Reviews|June 9, 2015
Developments in extracorporeal therapy for the poisoned patientNikunjkumar Patel, George P Bayliss
The AAPS Journal|July 12, 2018
Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and FesoterodineNikunjkumar Patel, Barbara Wisniowska, Sebastian Polak
Seminars in Nephrology|March 5, 2020
The Nephrologist's Management of Renal Cell Carcinoma After Kidney SurgerySusie L Hu
Clinical Kidney Journal|June 23, 2017
Does size matter? Kidney transplant donor size determines kidney function among living donorsMeenakshi Narasimhamurthy, Lachlan M Smith, Jason T Machan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 22, 2010
The role of graft-versus-host disease in haematopoietic cell transplantation-associated glomerular diseaseSusie L Hu
Journal of Pharmaceutical Sciences|November 21, 2016
Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and PosaconazoleRodrigo Cristofoletti, Nikunjkumar Patel, Jennifer B Dressman
Journal of Pharmaceutical Sciences|February 28, 2016
Differences in Food Effects for 2 Weak Bases With Similar BCS Drug-Related Properties: What Is Happening in the Intestinal Lumen?Rodrigo Cristofoletti, Nikunjkumar Patel, Jennifer B Dressman
The AAPS Journal|November 29, 2017
Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of CitalopramNikunjkumar Patel, Barbara Wiśniowska, Masoud Jamei, et al.
Transplantation|August 7, 2016
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney TransplantationDeirdre Sawinski, Nikunjkumar Patel, Brenda Appolo, et al.
Pageof 6